Interferon-γ and CXCL10 responses related to complaints in patients with Q fever fatigue syndrome.

Eur J Clin Microbiol Infect Dis 2018 Jul 26;37(7):1385-1391. Epub 2018 May 26.

Radboud Expertise Center for Q fever, Department of Internal Medicine, Division of Infectious Diseases 463, Radboud University Medical Center, P.O. Box 9101, 6500, HB, Nijmegen, The Netherlands.

Approximately 20% of patients with acute Q fever develop Q fever fatigue syndrome (QFS), a debilitating fatigue syndrome. This study further investigates the role of C. burnetii-specific IFNγ, but also IL-2, CXCL9, CXCL10, and CXLC11 production in QFS patients. C. burnetii-specific IFNy, IL-2, CXCL9, CXCL10, and CXCL11 production were tested in ex vivo stimulated whole blood of QFS patients who recovered from their complaints (n = 8), QFS patients with persisting complaints (n = 27), and asymptomatic Q fever seropositive controls (n = 10). With the exclusion of one outlier, stimulation with C. burnetii revealed significantly higher IFNy and CXCL10 production in QFS patients with persisting complaints (medians 288.0 and 176.0 pg/mL, respectively) than in QFS patients who recovered from their complaints (medians 93.0 and 85.5 pg/mL, respectively) (p = 0.041 and 0.045, respectively). No significant differences between groups were found for C. burnetii-specific IL-2, CXCL9, and CXCL11 production. These findings point towards a difference in cell-mediated immunity in QFS patients with persisting complaints compared to those who recovered from their complaints. Such a difference may aid to eventually diagnose QFS more objectively and might serve as an indicator of its underlying etiology.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10096-018-3265-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015096PMC
July 2018
12 Reads

Publication Analysis

Top Keywords

qfs patients
24
persisting complaints
12
patients persisting
12
recovered complaints
12
fatigue syndrome
12
il-2 cxcl9
12
fever fatigue
8
complaints medians
8
qfs
8
cxcl9 cxcl10
8
production qfs
8
patients recovered
8
patients
8
cxcl11 production
8
complaints
7
complaints difference
4
n = 27 asymptomatic
4
asymptomatic fever
4
fever seropositive
4
complaints compared
4

References

(Supplied by CrossRef)

NR Parker et al.
Lancet 2006

BP Marmion et al.
Lancet 1996

JG Ayres et al.
Lancet 1996

L Kampschreur et al.
Epidemiol Infect 2013

W Hoek Van der et al.
Euro Surveill 2012

SP Keijmel et al.
J Inf Secur 2016

AFM Jansen et al.
BMC Infect Dis 2017

SP Keijmel et al.
Clin Infect Dis 2017

G Morroy et al.
Epidemiol Infect 2016

Similar Publications